Infermedica formed a partnership with Sana Kliniken, one of the largest German healthcare providers, to provide patients with guidance and advice regarding their symptoms.
We will collaborate with Sana Kliniken developing a symptom checking system, built on Infermedica’s Symptom Checker. The tool is part of our AI-driven toolkit verified by medical doctors and refined with the knowledge from over 5 million medical cases. Thanks to this solution Sana’s clients will receive an even better customer experience and improve navigation on Sana’s website.
The medical and scientific background is crucial for us" explains Michael Rosenstock, Head of Sana Digital. "In addition, despite advanced background structures and algorithms, the Symptom Checker has a high level of user-friendliness.”
Certain groups of patients have difficulties in finding the desired information and the appropriate contact points. Unfamiliarity with medical terminology and being overwhelmed by extensive content leads to seeking medical assessment from the internet at large. The Symptom Checker integrated into Sana’s website will provide the patient with validated medical information and redirect them to trusted content.
“With the Symptom Checker, we have the opportunity to interact directly with potential patients, respond to their needs and provide them with appropriate recommendations,” explains Michael Rosenstock, Head of Sana Digital. “These answers do not only consist of the results and recommendations, but the Symptom Checker also guides the user via further links to related articles and videos on the Sana website. Thus, the user can access the growing number of medical issues and content from our network of experts,” continues Rosenstock.
“Our partnership with Sana, one of the German healthcare providers that share our goal to guide patients to the right care and passion for innovation is an important milestone on Infermedica’s roadmap. We are excited to form this collaboration and look forward to broadening access to healthcare through digitalization,” says Piotr Orzechowski, Chief Executive Officer at Infermedica.